A study of trends in pharmaceutical regulatory approval times for nine major markets in the 1990s

Drug Information Journal

Volumn 32, Issue 3, 1998, Pages 787-801

  Thomas, Kate E ^a   McAuslane, Neil ^c   Parkinson, Christopher ^c   Walker, Stuart R ^a   Luscombe, David K ^b  

^a Ctr for Medicines Res Intl   (United Kingdom)

^b UNIVERSITY OF WALES   (United Kingdom)

^c NONE

Author keywords

Approval times; New molecular entities; Regulatory review

Indexed keywords

NEW DRUG; ORPHAN DRUG;

ARTICLE; AUSTRALIA; CANADA; DRUG APPROVAL; DRUG MARKETING; DRUG RESEARCH; EUROPE; JAPAN; PRIORITY JOURNAL; UNITED STATES;

EID: 0031827058     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159803200319     Document Type: Article

References (21)

1. MacInnes R, MacFarlane FG, Drasdo AL, Lumley CE. International drug development: Efficiency and output (1980-1994). CMR Report 1995. CMR95-54R.
2. Evans NJB, Cunliffe PW. Study of Control of Medicines. 1987 ISBN 85197 081 9.
3. Baume P. A Question of Balance, report on the future of drug evaluation in Australia; Commonwealth of Australia 1991. Australian Government Publishing Service, Canberra.
4. Prescription Drug User Fee Act of 1992 Fiscal Year 1995. Report to Congress December 1995.
5. Barrowcliffe S. Developing a global regulatory strategy. Drug Inf J. 1994 28:525-531.
6. Harvey C, Lumley CE, Walker SR. A comparison of the review of a cohort of NCEs by four national regulatory authorities J Pharm Med. 1993;3:65-75.
7. Kaitin KI, Walsh HL. Are initiatives to speed the new drug approval process working? Drug Inf J. 1992;26:341-349.
8. Pieterson EA. A comparison of regulatory approval times for new chemical entities in Australia, Canada, Sweden, the United Kingdom, and the United States. J Clin Pharmacol 1992;32:889-896.
9. United States General Accounting Office Report to Congressional Requesters. PDA Drug Approval: Review time has decreased in recent years. 1995.
10. MacInnes R, Lumley CE, Walker SR. New chemical entity output of the international pharmaceutical industry from 1970 to 1992. Clin Pharmacol Ther. 1994;56(3):339-349.
11. Pharmaceutical Manufacturers Association New drug approvals 1990, 1991, 1992, 1993. Pharmaceutical Research and Manufacturers of America New drug approvals 1994, 1995.
12. Anon. Scrip 2033 June 13, 1995:18.
13. Health Canada. Average approval times for new active substances. Ontario: Health Canada; 1995.
14. Commission of the European Communities. Draft notice to applicants for marketing authorisation for medicinal products for human use in the European Community. Brussels; Commission of the European Communities: 1994:111/5944/94.
15. European Free Trade Association (EFTA) Scheme for the Mutual Recognition of Evaluation Reports on Pharmaceutical Products. Geneva: EFTA; 1995.
16. Stroud R. Drug Submission Evaluation: international comparison of performance standards and performance. Consulting Inc:1995.
17. Donnelley E, Ritchie J, French S. Company strategies to ensure a quick and efficient review: A transnational company. In Lumley CE, Walker SR (eds.) Improving the Regulatory Review Process: Industry and Regulatory Initiatives. Lancaster; Kluwer Academic Publishers: 1996:41-52.
18. Jefferys D. What determines the speed of review: Need for the product, quality of the dossier or efficiency of regulatory authorities? In Lumley CE, Walker SR (eds.). Improving the Regulatory Review Process: Industry and Regulatory Initiatives. Lancaster: Kluwer Academic Publishers; 1996:13-24.
19. Misawa K. What strategies should be considered for implementation by the end of the century? MHW perspective. In Lumley CE, Walker SR (eds.). Improving the Regulatory Review Process: Industry and Regulatory Initiatives, Lancaster: Kluwer Academic Publishers; 1996:139-148.
20. Morgenstern B. Company strategies to ensure a quick and efficient review: A Japanese company. In Lumley CE, Walker SR (eds.). Improving the Regulatory Review Process: Industry and Regulatory Initiatives. Lancaster: Kluwer Academic Publishers; 1996:33-40.
21. McAuslane N, Walker SR. International Regulatory Review Times. In Lumley CE, Walker SR (eds.). Improving the Regulatory Review Process: Industry and Regulatory Initiatives. Lancaster: Kluwer Academic Publishers; 1996:1-12.